Skip to Main Content

Is Concert Pharmaceuticals’ approach to drug development an artful way around patent law, or a safer route to build a drug? Maybe both.

The Massachusetts company is developing close facsimiles to the cystic fibrosis drug Kalydeco and the cancer drug Jakafi. They’re not quite biosimilars, nor are they generics — they’re therapies that are just different enough structurally from the established drugs to be considered unique pharmaceuticals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED